

Biosyngen boosts cell therapy GMP capabilities in Singapore

28 September 2022 | News

The facility will incorporate industry best practices and be a platform for process development in cell therapy manufacturing and application filing for its products



Singapore-based startup Biosyngen has signed to set up a cell therapy GMP facility which will serve as a base to develop the company's immunotherapy assets to address unmet needs in cancer treatment.

The facility, located in Solaris at Tai Seng, is 1,300 square metres and will be one of the largest in the country when it is completed. Developed by Soilbuild, the building is designed for biopharma and lifescience sector, it is an ideal site for biotechnology companies.

Biosyngen's GMP Facility will be open in June 2023 and produce GMP materials for clinical trials in Singapore and the region.

In consultation with ACTRIS, this facility will incorporate industry best practices and will be the company's platform for process development in cell therapy manufacturing and application filing for its products.

Shen Feiyu, Board Member of Biosyngen, was present with the Management of Soilbuild and Biosyngen to witness this milestone of the company.

"This strategic investment reflects our vision to give cancer patients a second chance by delivering more effective cancer care", said Isaac Chow, Country Head of Singapore and Chief Business Officer.

Image Caption: Signing of agreement by CEO Soilbuild, Roy Teo (L); COO Biosyngen, Michelle Chen (R).